Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | CLARITY: a Phase 2 trial using venetoclax and ibrutinib

Francesco Forconi • 10 Dec 2017
ASH 2017
Chronic Lymphocytic Leukemia Ibrutinib Venetoclax
CLARITY

CLARITY is a Phase II clinical trial studying the combination of ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL). In this video, Francesco Forconi, MD, DM, PhD, FRCPath from the University of Southampton, Southampton, UK discusses the results presented at the American Socienty of Hematology (ASH) 2017 Annual Meeting, held in Atlanta, GA.

More from Francesco Forconi

3:48
Using BTK degraders as a treatment strategy for patients with CLL
Francesco Forconi • 5 Oct 2023
3:24
Currently available approaches for treating CLL
Francesco Forconi • 5 Oct 2023
2:31
Treatment considerations for IgHV-unmutated and mutated CLL
Francesco Forconi • 4 Apr 2022
2:01
Novel combination therapies for the treatment of CLL
Francesco Forconi • 4 Apr 2022

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals